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High-grade Brainstem Glioma (BSG), also known as Diffuse Intrinsic Pontine Glioma (DIPG), is an incurable pediatric
brain cancer. Increasing evidence supports the existence of regional differences in gliomagenesis such that BSG is
considered a distinct disease from glioma of the cerebral cortex (CG). In an effort to elucidate unique characteristics of
BSG, we conducted expression analysis of mouse PDGF-B-driven BSG and CG initiated in Nestin progenitor cells and
identified a short list of expression changes specific to the brainstem gliomagenesis process, including abnormal
upregulation of paired box 3 (Pax3). In the neonatal mouse brain, Pax3 expression marks a subset of brainstem
progenitor cells, while it is absent from the cerebral cortex, mirroring its regional expression in glioma. Ectopic expression
of Pax3 in normal brainstem progenitors in vitro shows that Pax3 inhibits apoptosis. Pax3-induced inhibition of apoptosis
is p53-dependent, however, and in the absence of p53, Pax3 promotes proliferation of brainstem progenitors. In vivo,
Pax3 enhances PDGF-B-driven gliomagenesis by shortening tumor latency and increasing tumor penetrance and grade,
in a region-specific manner, while loss of Pax3 function extends survival of PDGF-B-driven;p53-deficient BSG-bearing mice
by 33%. Importantly, Pax3 is regionally expressed in human glioma as well, with high PAX3 mRNA characterizing 40% of
human BSG, revealing a subset of tumors that significantly associates with PDGFRA alterations, amplifications of cell cycle
regulatory genes, and is exclusive of ACVR1 mutations. Collectively, these data suggest that regional Pax3 expression not
only marks a novel subset of BSG but also contributes to PDGF-B-induced brainstem gliomagenesis.
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Brainstem Glioma (BSG) is a brain tumor that arises
anywhere in the brainstem, and is seen predominately in
children. Although BSG accounts for only 15-20% of all
pediatric brain tumors, it is the leading cause of death
for children with brain tumors [1]. The majority of BSG
(80-85%) are high grade, diffuse, and are located in the
pons—these are also known as Diffuse Intrinsic Pontine
Glioma (DIPG) and have an overall survival of less than
one year [1]. The term BSG hereafter will refer to high
grade BSG or DIPG. Conventional focal radiation therapy* Correspondence: oren.becher@duke.edu
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unless otherwise stated.remains the standard-of-care for these tumors, with no
documented additional benefit for any alternative treat-
ment [2].
Genetic alterations commonly found in BSG include
gains and/or activating mutations in platelet-derived
growth factor receptor alpha (PDGFRA), amplification
of genes involved in the receptor tyrosine kinase-Ras-
phosphoinositide 3-kinase signaling pathway or cell cycle
regulation, and a K27M mutation of histone H3.3 or 3.1
[3-9]. Recently, mutations in the ACVR1 gene have been
discovered in 20-32% of cases [10-13], as well as muta-
tions in the PPM1D gene [11,14]. The most frequent
tumor suppressor lost is TP53, with INK4A-ARF less
commonly absent at the genomic level but possibly si-
lenced through alternative mechanisms [3,6,15,16]. Previ-
ous work on BSG has characterized distinct subsets of the
disease, including mesenchymal and oligodendroglial [5],al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[10] or H3-K27M and wildtype [6]. Together, these classi-
fications highlight the heterogeneity of this disease and
the likelihood that effective treatment will require an
understanding of the mechanisms driving the growth of
each individual subtype.
In addition to the heterogeneity within pediatric BSG,
increasing evidence suggests that this disease is biologic-
ally distinct not only from adult glioma but also from
pediatric supratentorial glioma in terms of genetic alter-
ations and expression signatures [3-5]. Gliomas arising in
the midline of the central nervous system (including the
brainstem) commonly harbor the H3.3/3.1-K27M muta-
tion only, while gliomas that arise in the cerebral cortex
may contain an alternative H3.3-G34R/V mutation [6-9].
Regional differences in glioma may be a consequence in
part of innate differences in the cells from which the tu-
mors arise. Several studies have shown that NSCs from
various regions of the brain differ in their capacity to
respond to oncogenic stimuli in vitro and in vivo [18,19].
In addition, human infratentorial and supratentorial low-
grade gliomas have distinct expression signatures corre-
sponding to normal astrocytes and NSCs from their
respective regions [20], while the expression patterns of
G34R/V and K27M mutant gliomas mimic the develop-
mental region in which they arise [8].
One gene found to be expressed at higher levels in
infratentorial compared to supratentorial low-grade gli-
oma is paired box 3 (PAX3) [20]. Pax3 is a developmental
transcription factor that displays a regionalized expression
pattern in the neural tube, neural crest, and somite of the
vertebrate embryo, with expression decreasing as differen-
tiation progresses [21]. Early in embryogenesis, Pax3 is
transiently expressed in the posterior and dorsal neural
tube [22-24]. This leads to its expression in the developing
CNS to be localized to infratentorial structures such as
the brainstem and cerebellum, but not to supratentorial
domains such as the cerebral cortex (see P4 in situ
hybridization for Pax3 in [25]). Pax3 is not only necessary
for the proper specification of these developing tissues
[21,26-28], but also for cell survival as homozygous loss of
Pax3 in the mouse leads to severe neural crest and neural
tube defects, attributable to an induction of p53-dependent
apoptosis [29-31].
Ectopic expression of Pax3 is found to be pro-
tumorigenic in sarcomas and neural crest-derived
tumors such as melanoma and neuroblastoma [21].
However its role in glioma is less well-understood.
Pax3 is re-expressed and upregulated in human glioma
relative to normal brain tissue with its expression in-
creasing concomitant with World Health Organization
Grade and worsening prognosis, irrespective of tumor lo-
cation [32]. Functionally, Pax3 has been implicated in pro-
moting proliferation and invasion and inhibiting apoptosisof glioma cell lines, and promoting growth of glioma sub-
cutaneous xenografts [33].
In this study, we sought to gain insight into the unique
attributes of BSG by comparing it to high-grade glioma
of the cerebral cortex (CG). In an expression array com-
paring mouse BSG and CG induced by PDGF-B overex-
pression and Ink4a-ARF loss [34], we identified Pax3 as
being a brainstem-specific marker. Pax3 is regionally
expressed in the neonatal mouse brain as well, charac-
terizing a subset of Nestin progenitors in the brainstem
but not in the cerebral cortex. Ectopic overexpression of
Pax3 in brainstem progenitors inhibits apoptosis in vitro
and enhances PDGF-B-induced brainstem gliomagenesis
in vivo, in a region-specific manner. In the absence of
p53, while Pax3 no longer inhibits apoptosis, it increases
proliferation in vitro and maintains its pro-tumorigenic
role in vivo. Importantly, the regional expression pattern
of Pax3 is mirrored in human glioma, revealing a subset
of BSG with high PAX3 expression that associates with
alterations in PDGFRA and cell cycle regulatory genes
and is exclusive of ACVR1 mutations. These data suggest
that regional expression of Pax3 contributes to PDGF-B-
induced brainstem gliomagenesis and characterizes a
subset of human BSG.
Materials and methods
Mice
Nestin-Tva (Ntv-a) and Ntv-a;Ink4a-ARF−/− [34] and Ntv-
a;p53fl/fl mice [35] have been described. Olig2-eGFP-L10a
[36,37] were bred to Ntv-a;Ink4a-ARF−/− mice to generate
Ntv-a;Ink4a-ARF−/−;Olig2-eGFP-L10a mice. Pax3-floxed
mice [38] were bred to Ntv-a;p53fl/fl mice to generate
Ntv-a;p53fl/fl;Pax3fl/fl (Pax3-KO) and control Ntv-a;p53fl/fl;
Pax3+/+ mice. Nestin-CFPnuc mice have been previously
described, and express the cyan fluorescent protein fused
to a nuclear localization signal under the control of the
regulatory elements of the Nestin gene [39]. For genotyp-
ing, gDNA was isolated from mice using the REDExtract-
N-Amp Tissue PCR Kit (Sigma) per the manufacturer’s
protocol, using previously published primers. All work with
mice was done in accordance with the Duke University
Animal Care and Use Committee and the Guide for the
Care and Use of Laboratory Animals.
RCAS/Tv-a glioma mouse modeling
In the RCAS/Tv-a glioma mouse modeling system,
avian retroviruses (produced from RCAS plasmids) in-
fect mouse cells expressing Tv-a (the receptor for
RCAS viruses). DF1 cells (ATCC) were cultured and
transfected with RCAS plasmids as described [35] using
Fugene 6 or X-TremeGENE 9 (Roche). RCAS-Y, RCAS-
PDGF-B, and RCAS-Cre plasmids are described [40].
RCAS-Pax3 plasmid was obtained from Andrew Bendall
(University of Guelph, Ontario) [41]. RCAS-H3.3-K27M
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Rockefeller University, New York) [42]. Generation of
PDGF-B-induced brainstem glioma [34,35] and cerebral
cortex glioma [43] were as described. Briefly, 1×105 DF1
cells transfected with RCAS plasmids and producing
RCAS viruses, were injected into the brainstem or cerebral
cortex of neonatal Ntv-a pups (postnatal day 2–4) in 1 μL
volume using a custom Hamilton syringe. Combinations
of viruses were injected at a 1:1 or a 1:1:1 ratio, and
RCAS-Y transfected DF1 cells were used as a negative
control. Injected mice were monitored daily and eutha-
nized with CO2 upon appearance of signs of brain tumors
(enlarged head, ataxia, weight loss up to 25%) or at 12
weeks post-injection in the absence of symptoms.
FACS of Olig2-eGFP-L10a glioma
Brainstem or Cerebral Cortex Gliomas from Ntv-a;
Ink4aARF−/−;Olig2-eGFP-L10a mice injected with RCAS-
PDGF-B were harvested and dissociated into a single cell
suspension as described [35]. Briefly, tissue was digested
in papain (Worthington) and DNAse (Sigma Aldrich) at
37°C, followed by three cycles of triturations in ovomu-
coid (Worthington) and centrifugation at 600 rpm. The
resulting cells were passed through a 70 μm strainer, an
aliquot of cells was set aside for the unsorted control, and
the remainder of cells were sorted using a FACSVantage
sorter (BD Bioscience) by the Duke Cancer Institute Flow
Cytometry Core into GFP+ and GFP- populations. Cell
populations were centrifuged, washed in PBS, snap frozen
and stored at −80°C for mRNA isolation.
Immunofluorescence
Ntv-a or Nestin-CFPnuc pups were sacrificed at P3 and
their whole brains were fixed in 4% PFA in PBS for
24 hours, cryopreserved in 30% sucrose in PBS for 24–48
hours, followed by embedding in OCT on dry ice/ethanol.
Blocks were sectioned using either a Shandon or Leica
Cryostat into 12 μm thick sections in a sagittal orientation.
Sections were rehydrated in PBS-T (0.1% Triton-X100)
and blocked in PBS-T with 10% normal goat serum. Pri-
mary antibodies were diluted in PBS-T with 1% BSA over-
night at 4 degrees, and secondary antibodies were diluted
in PBS-T for 1 hour. Antibodies used were anti-PAX3
(DSHB, concentrated form, 1:200), and anti-GFP (Invitro-
gen, 1:200); AlexaFluor-488 and −594 secondary antibodies
(Invitrogen) were used at 1:200. Slides were mounted with
Vectashield with Dapi (Vector Laboratories) and imaged
using a Zeiss Axio Imager.
In order to quantify PAX3 and Nestin expression, three
Nestin-CFPnuc P3 mice were analyzed. High-powered
(20x) pictures of the PAX3-expressing cells in each brain-
stem region (midbrain, dorsal pons, mid pons, and ventral
pons) were taken, 1–3 images per region per section, until
at least 6 sections were represented for each region. Allpictures were taken using a Zeiss Axio Imager and con-
sistent camera settings. For the cerebral cortex, 2 random
20x images were taken in at least 6 sections per mouse.
Using Metamorph Premier software, a threshold was set
for positive Nestin and PAX3 staining in each image. For
each marker, the same threshold was applied to each
image across the dorsal, mid, and ventral pons regions for
each section. For the midbrain region, the threshold for
PAX3 was consistently lowered slightly to accommodate a
lower intensity of the PAX3 staining compared to the
other regions. The threshold for Nestin staining in the
cerebral cortex was set separately, and remained the same
for all sections and all mice. There was no positive nuclear
PAX3 staining in any cerebral cortex section. The positive
nuclei (size > 200) for each marker were then counted
using Integrated Morphometry Analysis. A color thresh-
old was then applied to each Nestin/PAX3 overlay (the
same threshold was used across regions for each section),
and the number of double-positive cells were counted as
described above. The cell counts for each region per sec-
tion were totaled, and the percentage of Nestin + cells that
were double positive per region was calculated. The per-
centages were averaged together across sections of the
same mouse to generate a mean percentage for each re-
gion per mouse.
Mouse and human expression analysis
Frozen BSG and CG samples, along with brainstem and
cerebral cortex from age-matched non tumor-bearing
mice of the same genetic background (n = 3 for all
groups), were sent to Expression Analysis (EA, Durham,
NC) for total mRNA isolation and hybridization to Affy-
metrix GeneChip Mouse Genome 430 2.0 Arrays. Total
mRNA samples isolated from Olig2-eGFP-L10a-positive
PDGF-B;Ink4aARF−/− glioma cells were sent to EA for
hybridization to the same arrays. Data was analyzed
using Partek Genomics Suite (Partek Incorporated) for
quality control, Robust Multi-Array (RMA) was used for
normalization, and differentially expressed genes were
determined by one-way ANOVA using the cutoffs de-
scribed in the text.
Human BSG and CG samples with expression data
available from St. Jude [4,44] were selected for analysis.
Log-scale Robust Multiarray Analysis (RMA) from the
affy [45] package in Bioconductor [46] was used for
normalization to eliminate systematic differences across
the arrays. Differentially expressed genes between brain-
stem and cerebral cortex glioma samples were identified
using the limma [47] package in Bioconductor, which uti-
lizes an empirical Bayes’ approach for parameter esti-
mation and significance testing. The False Discovery
Rate (FDR) method was employed to control for multiple
hypothesis testing. To compare gene expression differ-
ences within the brainstem samples, RMA normalization
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based on their normalized PAX3 expression levels (probe
231666_at). Arrays where PAX3 had a normalized
expression value > 4 were classified as PAX3-High, while
all others were classified as PAX3-Low. Identification of
genes differentially expressed between the two groups was
calculated using limma as described above. These same
classifications of PAX3-High and PAX3-Low were used for
associations with genetic alterations, where the genetic al-
terations were acquired from previously published data
[4,9,11,48].
Human BSG and CG samples with expression data
available from Necker-Sick Children [5] were selected for
an independent analysis. The Agilent microarray data was
processed and normalized using the limma [47] package
in Bioconductor [46]. The normexp method (normal + ex-
ponential convolution model) was used to correct for
background intensities. Quantile normalization was used
to eliminate systematic differences across all of the arrays.
Differentially expressed genes between brainstem and
cerebral cortex glioma samples were determined using the
methods described above for the first dataset. To compare
gene expression differences within the brainstem samples,
arrays were classified based on their PAX3 expression
levels (probe name: A_23_P502706). Arrays with a PAX3
expression level > 7 were classified as PAX3-High, whereas
all others were classified as PAX3-Low. Identification of
genes differentially expressed between the two groups was
calculated using limma as described above.
In vitro infection of brainstem progenitors with RCAS
viruses
Normal brainstem was isolated from Ntv-a or Ntva;p53fl/fl
postnatal day 3 (P3) pups and was digested and dissoci-
ated as described above for Olig2-eGFP-L10a tumors.
Cells were cultured in DMEM supplemented with 10%
FBS, 2 mM L-glutamine, 100 units/mL penicillin and
100 μg/mL streptomycin at 37°C and 5% CO2, and pas-
saged a maximum of 3 times for experiments. Cells were
plated in clear 6-well plates for Annexin V assays, clear
96-well plates for BrdU assays, and white-walled, clear-
bottomed 96-well plates for Caspase 3/7 assays.
To concentrate RCAS viruses, DF1 cells transfected
with RCAS plasmids were passaged a minimum of 6 times
from transfection, and then passaged 1:12. After 3 days,
virus-containing media was harvested, centrifuged to re-
move cell debris, filtered through 0.45 μm pores, and con-
centrated 100-fold using Retro-X Concentrator (Clontech)
per the manufacturer’s instructions.
Brainstem progenitors were plated and infected with
RCAS viruses at 1:100. Assays were conducted 3–5
days post-infection, or were split when confluent and
subsequently plated for assays. For BrdU assays, the
Cell Proliferation ELISA, BrdU Colorimetric kit (Roche)was utilized, per the manufacturer’s instructions using a
Molecular Devices Versa Max Tunable Microplate reader.
Caspase 3/7 activity was measured using the ApoToxGlo
Triplex assay (Promega) per the manufacturer’s instruc-
tions using a Turner Biosystems Modulus Microplate
Reader. To measure the percentage of cells staining
positive for Annexin V, the FITC Annexin V Apoptosis
Detection Kit I (BD Pharmingen) was utilized per the
manufacturer’s instructions. For cell counting experi-
ments, 50,000 infected cells were plated in 6 well plates
in duplicate. For each time point, 2 wells of each line
were trypsinized and counted with a Sceptor 2.0 Cell
Counter (Millipore). All experiments were done a mini-
mum of three times on at least three independent prep-
arations of progenitor cells.Tumor grading and immunohistochemistry
Tumor samples fixed in 10% formalin were embedded in
paraffin by the Duke Pathology Core and cut into 5 μm
thick sections using a Leica RM2235 microtome. H&E
staining was performed using standard protocols. Tumor
grading was done using the following criteria: Grade II gli-
oma indicated by increased cellular density only; Grade III
glioma indicated by the presence of microvascular prolif-
eration; Grade IV glioma indicated by the presence of
pseudopalisading necrosis. Immunohistochemistry (IHC)
was performed using an automated processor (Discovery
XT, Ventana Medical Systems, Inc.). Anti-PCNA antibody
(Calbiochem) was used at 1:2000.PCR
DNA was isolated from frozen tumors using the DNeasy
Blood and Tissue Kit (Qiagen) per the manufacturer’s in-
structions. Detection of the recombined Pax3-floxed allele
was performed using previously published primers [38]
and 60°C annealing temperature. For RT-PCR (both con-
ventional and real time), cultured cells or snap frozen tu-
mors were processed for mRNA isolation using the
RNeasy Mini kit (QIAGEN) per the manufacturer’s proto-
col. cDNA was synthesized from total mRNA using
SuperScript II and OligodT primer (Invitrogen). RT-PCR
primers for PDGF-B, Forward: 5’-AGTGACCACTC-
GATCCGCTCCT-3’, Reverse: 5’- TTTGGGGCGTTTT
GGCTCGCTG-3’, 55°C annealing temperature. PDGF-B
primers amplify both mouse and human PDGF-B cDNA.
qRT-PCR reactions were set up with iQ SYBR Green
Supermix (BioRad) and run on a Bio-Rad iQ5 Multicolor
Real-Time PCR Detection System. Primers for Pax3,
Forward: 5’- TCCATCCGACCTGGTGCCAT-3’, Reverse:
5’- TTCTCCACGTCAGGCGTTG, and Actin, Forward:
5’- TATTGGCAACGAGCGGTTCC-3’, Reverse: 5’- GGC
ATAGAGGTCTTTACGGATGTC-3’; 60°C annealing
temperature. Relative gene expression levels were generated
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Western blot
Frozen tumors were either grinded with a mortar and pes-
tle on liquid nitrogen followed by lysis in RIPA buffer con-
taining 1x Protease Inhibitor Cocktail (Sigma Aldrich),
10 mM PMSF, 50 mM NaF, 1 mM NaVO4, and 1 mM
DTT or lysed and homogenized in the same buffer using a
Glas-Col Variable Speed-Reversible Homogenizer set to a
motor speed of 80 followed by sonication using a Brason
Sonifier 250. Cleared and denatured lysates were run on a
NuPAGE 4-12% Bis-Tris gradient gel (Invitrogen), and
transferred onto nitrocellulose membrane using the
iBlot (Invitrogen). Antibodies were diluted in Odyssey
Blocking Buffer (Li-Cor) with 0.2% Tween-20. Blots
were imaged using the Odyssey (Li-Cor) per the manufac-
turer’s instructions. Antibodies used were: anti-PAX3
(DSHB, concentrated form, 1:1000) and anti-ACTIN
(Santa Cruz Biotechnology, 1:500). Secondary antibodies
from Li-Cor were used at 1:10,000 for IRDye800CW or
1:20,000 for IRDye680LT.
Statistical analysis
Statistics were calculated using GraphPad Prism 5 soft-
ware. In vitro assays were performed a minimum of 3
times using cells from at least 3 independent P3 litters.
Data are represented as the mean with SEM, using stu-
dent’s paired t-test. qRT-PCR for Pax3 in mouse tissue
was analyzed using student’s unpaired t-test. In vivo ana-
lyses were performed using log-rank test (for survival)
and Fisher’s exact test (for tumor penetrance and grade).
For analyses of human data, unpaired t-test was used for
the age at diagnosis of PAX3-Low versus PAX3-High tu-
mors, and Fisher’s exact test was used to test for signifi-
cance of the association between high Pax3 expression
and genetic alterations.
Results
Mouse Brainstem Glioma and Cerebral Cortex Glioma
have distinct gene expression signatures
In order to identify regional differences in glioma, and in
particular unique characteristics of those arising in the
brainstem, we generated mouse Brainstem Glioma (BSG)
and Cerebral Cortex Glioma (CG) by injecting RCAS-
PDGF-B virus-producing cells into the brainstem or cere-
bral cortex, respectively, of postnatal day 2–4 (P2-4)
Nestin-Tv-a(Ntv-a);Ink4aARF−/− mice (Figure 1a) [34,43].
The gene expression profiles of the resulting tumors were
first compared to their normal tissue counterparts. Using
an FDR-adjusted p-value <0.05 and fold-change ≥2.0,
7,869 genes were differentially expressed between normal
cortex (NC) and CG (Figure 1b, Additional file 1: Table S1),
while 7,263 genes were altered in BSG compared to normalbrainstem (NBS) (Figure 1b, Additional file 2: Table S2).
Of the latter group, 2,547 genes were specific to the brain-
stem gliomagenesis process and were not altered during
gliomagenesis in the cerebral cortex (Figure 1b). In
addition, the comparison between BSG and CG revealed
only 23 genes differentially expressed between these two
types of tumors (Figure 1b-c, Additional file 3: Table S3),
including upregulation of Irx5 and Pax3 and downregula-
tion of Bmp4 and Foxg1. We were interested in genes that
functionally contribute to the brainstem gliomagenesis
process, and so when these 23 genes were intersected with
the 2,547 BSG-associated genes, 10 probes, representing 8
brainstem-specific gliomagenesis genes, were identified
(Figure 1b, Table 1).
The expression array comparing Brainstem and Cere-
bral Cortex Gliomas described above was conducted with
whole tumor tissue. Therefore it is possible that non-
neoplastic cells contributed to some of the expression
differences. To investigate this, we utilized the Olig2-
eGFP-L10a reporter strain [36,37], in which the eGFP-
L10a fusion protein is expressed under the control of
the Olig2 promoter. As Olig2 expression marks all tumor
cells of our glioma model [34], this effectively labels tumor
cells with GFP. Ntv-a;Ink4a-ARF−/−;Olig2-eGFP-L10a mice
were injected with RCAS-PDGF-B into the brainstem or
cerebral cortex to generate BSG or CG, respectively, within
4–6 weeks from injection (Additional file 4: Figure S1a).
Tumors were harvested, dissociated, and sorted into GFP-
positive and -negative populations. The GFP-positive
fractions were analyzed for gene expression differences
by microarray, and 118 genes were found differentially
regulated between Olig2-BSG and Olig2-CG tumor
cells (Additional file 4: Figure S1b, Additional file 5:
Table S4). Importantly, of the 8 brainstem-specific glio-
magenesis genes in Table 1, the genes highlighted in
bold were also differentially regulated between Olig2-
BSG and Olig2-CG cells, and presumably play a role in
BSG tumor cell biology.
Pax3 expression characterizes mouse Brainstem Glioma
Among the 8 brainstem-specific gliomagenesis genes
identified in this screen, 3 independent probes for the
developmental transcription factor paired box 3 (Pax3)
showed upregulation in BSG over CG and over normal
brainstem (Table 1, Figure 2a). This differential expres-
sion pattern was confirmed via qRT-PCR (Figure 2b).
Pax3 was undetectable by qRT-PCR in normal cerebral
cortex or CG tissue (n = 3 for each, data not shown). Im-
portantly, Pax3 was also differentially expressed between
Olig2-BSG and -CG cells, with increased expression in
BSG relative to CG (Figure 2c, Additional file 5: Table S4).
To determine whether Pax3 expression is confined to
the Olig2-tumor cell compartment of BSG, qRT-PCR
for Pax3 was conducted on the sorted GFP-positive
Brainstem
Injection
Cerebral Cortex
Injection
Mid
Brain
Pons
Medulla
a
b c
Figure 1 Regional differences in PDGF-B-driven mouse glioma. a Glioma was initiated in the mouse by injecting RCAS-PDGF-B virus into the
brainstem or cerebral cortex of neonatal Ntv-a;Ink4a-ARF−/− mice. Shown is a sagittal section of a wildtype postnatal day 4 brain, stained with
H&E, indicating the location of brainstem and cerebral cortex injections. Scale bar is 1 mM. b-c Expression profiling was conducted on the
resulting Brainstem Glioma (BSG) and Cerebral Cortex Glioma (CG) and compared with age-matched normal brainstem (NBS) and normal cerebral cortex
(NC), n = 3 for each. b Venn diagram showing the intersection of genes differentially expressed between NBS and BSG (green circle), between NC and
CG (blue circle), and between BSG and CG (red circle). c Hierarchical clustering of 23 genes differentially regulated between BSG and CG. FDR-adjusted
p-value <0.05 and fold-change ≥2.0.
Table 1 8 Genes associated with brainstem gliomagenesis but not cerebral cortex gliomagenesis and differentially
expressed between Brainstem Glioma (BSG) and Cerebral Cortex Glioma (CG) in the mouse
Gene symbol Gene title Fold-change BSG vs NBS p-value Fold-change BSG vs CG p-value
Pax3 paired box gene 3 4.96 1.04E-05 8.44 1.20E-06
Pax3 paired box gene 3 3.87 2.19E-04 6.32 2.45E-05
Irx5 Iroquois related homeobox 5 (Drosophila) 3.35 2.67E-03 19.01 6.15E-06
Pax3 paired box gene 3 2.61 2.86E-04 3.70 3.24E-05
Pcyt1b phosphate cytidylyltransferase 1, choline, beta isoform 2.49 1.11E-05 2.46 1.24E-05
4933436C20Rik RIKEN cDNA 4933436C20 gene 2.47 4.35E-05 2.99 1.08E-05
Myo5b myosin VB −2.41 5.53E-03 −7.59 2.41E-05
Bmp4 bone morphogenetic protein 4 −2.57 3.47E-07 −2.77 1.94E-07
Chl1 cell adhesion molecule with homology to L1CAM −7.21 2.66E-06 −12.91 3.66E-07
Al314604 expressed sequence Al314604 −45.25 8.64E-11 −8.89 7.21E-09
Genes in bold are also differentially expressed between Olig2-eGFP-L10a BSG and CG (See Additional file 5: Table S4). NBS = Normal brainstem.
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This revealed that Pax3 expression is primarily found
within the Olig2-tumor cell compartment of BSG
(Figure 2d). Pax3 mRNA was undetectable by qRT-PCR
in all compartments of Olig2-eGFP-L10a CG (n = 3, data
not shown).
PAX3 protein can also be detected at higher levels in
mouse BSG than CG by western blot (Figure 2e). To de-
termine whether high expression of PAX3 occurs in
p53-deficient BSG, we injected Ntv-a;p53fl/fl mice with
DF1 cells producing RCAS-PDGF-B and RCAS-Cre vi-
ruses [35]. In the tumors that arose in these mice, we
found PAX3 protein expression at levels comparable to
those found in Ink4aARF-deficient tumors (Figure 2e).
In addition, to investigate whether the regional expres-
sion pattern of Pax3 is relevant in the context of thecommonly occurring H3.3-K27M histone mutation, we
injected Ntv-a;p53fl/fl mice with DF1 cells producing
RCAS-PDGF-B, RCAS-H3.3-K27M, and RCAS-Cre viruses
[42]. As shown in Figure 2f, we see high levels of PAX3
protein in PDGF-B;H3.3-K27M;p53-deficient gliomas initi-
ated in the brainstem, but not in the cerebral cortex.
Collectively, these data indicate that Pax3 is a brainstem-
specific marker of mouse PDGF-B-driven glioma in the
context of Ink4aARF-deficiency, p53-deficiency, as well as
H3.3-K27M expression.
Pax3 is regionally expressed in the neonatal mouse brain
High Pax3 expression characterizes PDGF-B-driven mouse
BSG while its expression is lower in glioma arising in the
cerebral cortex. We speculated that enhanced PDGF sig-
naling induced by PDGF-B ligand might upregulate Pax3
Misuraca et al. Acta Neuropathologica Communications 2014, 2:134 Page 8 of 17
http://www.actaneurocomms.org/content/2/1/134in the brainstem and be responsible for its high expression
level. However, when brainstem progenitor cells iso-
lated from Ntv-a P3 mice were infected in vitro with
RCAS-PDGF-B virus, Pax3 mRNA levels did not in-
crease (Figure 3a).
As Pax3 is a developmental transcription factor whose
expression normally decreases as differentiation proceeds,
we next investigated whether Pax3 is expressed at the time
of tumor initiation in the brainstem, which in our mouse
model is P2-4. By Western blot, PAX3 protein was de-
tected in wildtype P3 brainstem but not cerebral cortex
(Figure 2e, cerebellum is shown as a positive control), con-
sistent with its expression pattern in glioma. To further
characterize the expression pattern of Pax3 in the develop-
ing brain, we conducted immunofluorescence for PAX3
protein in the P3 mouse brain and found several regions of
expression within and around the developing brainstem.
Distinct clusters of cells immunoreactive for PAX3 were
found in the dorsal, mid, and ventral pons (Figure 3b-c,
Additional file 6: Figure S2a-b, upper panels). In addition,RC
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We next investigated whether Pax3 expression charac-
terizes any Nestin-progenitors, the targeted cell-of-origin
in our glioma mouse model, in the P3 mouse brainstem.
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progenitors in the dorsal pons, the roof and floor of the
4th ventricle, and the midbrain (Figures 3b, d, e, and
Additional file 6: Figure S2c, lower panels, and quanti-
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http://www.actaneurocomms.org/content/2/1/134co-expression of Nestin and PAX3 in the ventral or
mid pons and none in the cerebral cortex (Figure 3c, f,
and Additional file 6: Figure S2b, lower panels, quantified
in Figure 3g). Thus the regional expression pattern of
Pax3, and its co-expression with Nestin, in the neonatal
mouse brain correlates with its expression in glioma.
Pax3 inhibits apoptosis of brainstem progenitor cells
To investigate the functional role of Pax3 in brainstem pro-
genitor cells, the brainstem region (including the midbrain
and pons) from P3 Ntv-a mice was isolated, dissociated,
and cultured in vitro. The Nestin-expressing progenitor
cells were infected with RCAS-Y, RCAS-Pax3, RCAS-
PDGF-B, or a 1:1 combination of RCAS-Pax3 and RCAS-
PDGF-B (Figure 4a and Additional file 7: Figure S3a).
RCAS-Pax3 alone, or in combination with PDGF-B, did
not directly increase proliferation of brainstem progenitors
based on BrdU incorporation (Additional file 7: Figure
S3b). However, Pax3 inhibited basal apoptosis as evidenced
by caspase 3/7 activation (Figure 4b). Similarly, Pax3 over-
expression reduced the percentage of cells staining positive
for Annexin V, a marker for early apoptosis, when com-
pared to RCAS-Y-infected cells (Figure 4c).
Pax3 enhances PDGF-B-induced brainstem gliomagenesis
in vivo
In order to determine if Pax3-induced inhibition of
apoptosis is sufficient to induce glioma in vivo, P3 Ntv-a
mice were injected in the brainstem with RCAS-Pax3,
RCAS-PDGF-B, or a 1:1 mixture of both viruses. While
PDGF-B overexpression alone led to asymptomatic low-
grade glioma in 5 out of 20 mice, Pax3 overexpression
alone did not lead to tumor formation (Figure 5a-c).RC
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Figure 4 Pax3 inhibits apoptosis of brainstem progenitor cells. Brainst
with the indicated RCAS viruses. a qRT-PCR for Pax3 in the infected progenitor c
to RCAS-Y-infected cells, p = 0.007 paired t-test, and levels for PDGF-B + P
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percentage of RCAS-Y-infected cells that were AnnexinV+/PI-. p = 0.005, pWhen compared to PDGF-B injection alone, the addition
of Pax3 to PDGF-B significantly reduced survival
(Figure 5a) and increased tumor penetrance to 20 out
of 25 mice (p = 0.0003, Figure 5b). Importantly, addition
of Pax3 to PDGF-B overexpression caused a subset of
tumors to progress to high-grade glioma based on the pres-
ence of microvascular proliferation (0/5 PDGF-B versus
5/20 PDGF-B + Pax3 high-grade, p = 0.056, Figure 5b-c).
The Pax3-induced high-grade gliomas harbored increased
proliferation compared to the low-grade tumors induced
by PDGF-B alone based on PCNA staining (Figure 5d).
The pro-tumorigenic role of Pax3 in glioma is
brainstem-specific, as co-injection into the cortex of both
PDGF-B and Pax3 did not significantly reduce survival or
increase tumor penetrance (p = 1.0) or grade (p = 1.0)
compared to injection of PDGF-B alone (Additional file 8:
Figure S4). Therefore, in the presence of enhanced
PDGF-B signaling, Pax3 is sufficient to generate ag-
gressive high-grade BSG, a feat that PDGF-B alone
cannot achieve in the brainstem.Pax3 promotes proliferation and gliomagenesis in the
brainstem independent of p53
As the majority of human BSG are p53-deficient, we in-
vestigated the role of Pax3 in our BSG mouse model in
the absence of this tumor suppressor. Brainstem progeni-
tor cells were isolated from P3 Ntv-a;p53fl/fl mice and in-
fected with RCAS-Cre to knock-out p53 along with either
RCAS-Y or RCAS-Pax3. In the absence of p53, Pax3 over-
expression no longer inhibited caspase 3/7 activation
(Figure 6a). However, in these p53-deficient progenitor
cells, Pax3 overexpression did lead to a significant increasePa
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http://www.actaneurocomms.org/content/2/1/134in cell proliferation, indicated by BrdU incorporation
(Figure 6b) and cell counting (Figure 6c-d).
In order to test whether Pax3 is functionally required
for the initiation or progression of p53-deficient BSG
in vivo, we crossed conditional Pax3 knockout mice
[38] into our p53-deficient BSG model [35]. Neonatal
Ntv-a;p53fl/fl;Pax3fl/fl mice (Pax3-KO) and Ntv-a;p53fl/fl;
Pax3+/+ mice (Control), were injected with RCAS-PDGF-B
and RCAS-Cre. Although both groups of mice succumbed
to high-grade BSG, the Pax3-KO mice displayed a
significant 33% increase in survival (median survival
38 days versus 28.5 days, Figure 6e). Recombination of
the Pax3-floxed allele was confirmed via PCR of gDNA
and loss of PAX3 protein expression was confirmed viaWestern blot in Pax3-KO tumors (Additional file 9:
Figure S5a-b). The increased survival of Pax3-KO mice
suggests that Pax3 functionally contributes to brainstem
gliomagenesis, although it is ultimately not required as
tumors can quickly evade the loss of Pax3.
High Pax3 expression defines a novel subset of human
BSG
To correlate our observations regarding Pax3 expression
and function in mouse glioma with human disease,
pediatric BSG (all of which were characterized as DIPG)
and CG samples were utilized from previously published
gene expression profiles, one comprised of post-treatment
autopsies [4,44], and one comprised of pre-treatment
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http://www.actaneurocomms.org/content/2/1/134biopsies [5]. The BSG and CG profiles from each dataset
were compared, generating lists of significantly differentially
expressed genes (FDR-adjusted p-value <0.05, Additional
file 10: Table S5 and Additional file 11: Table S6). PAX3
was upregulated in BSG relative to CG in both datasets,
3.7-fold in the autopsy samples (Figure 7a), and 1.8-fold in
the biopsy samples (Figure 7b).
Interestingly, high PAX3 expression characterized ap-
proximately 40% of the BSG samples in both datasets
(11/28, Figure 7a, and 11/25, Figure 7b). To glean infor-
mation regarding the tumors with high PAX3 expres-
sion, we first compared gene expression profiles of the
PAX3-Low versus PAX3-High BSG samples from both
datasets. Besides PAX3, there were very few genes that
met the criteria for significance (adjusted p-value <
0.05, Additional file 12: Table S7 and Additional file 13:
Table S8), and none that shed any additional light on
the biology of the PAX3-High subset. We next comparedthe genetic alterations occurring in PAX3-Low versus
PAX3-High BSG samples from Figure 7a [4,9,11,48]. As is
shown in Figure 7c, Table 2, and Additional file 14:
Table S9, high PAX3 expression significantly associ-
ated with wildtype ACVR1, PDGFRA amplification or
mutation, and CDK4/6-CCND1/2/3 amplification. In
addition, PPM1D and H3.1-K27M mutations were
found exclusively in PAX3-Low tumors (27% and 18%,
respectively), although these relationships were not sig-
nificant due to their low frequency. The majority of
PAX3-High tumors also contained TP53 alterations
(82%) and the H3.3-K27M mutation (82%). Lastly, com-
pared to children with PAX3-Low BSG, those harboring
PAX3-High BSG were significantly older at diagnosis
(Figure 7d). Collectively, these data describe a novel subset
of human BSG with high Pax3 expression that are
commonly characterized by increased PDGF signaling,
and highlight an important regional difference between
Figure 7 High Pax3 expression characterizes a subset of human Brainstem Glioma. a-b Previously published expression profiles of human
BSG and CG samples: post-treatment autopsy samples from St. Jude (a) and pre-treatment biopsy samples from Necker-Sick Children
(b) were analyzed for gene expression differences as described in Materials and Methods. Log expression level of PAX3 in BSG versus CG.
Red circles indicate the 11/28 (a) and 11/25 (b) of BSG samples with high PAX3 expression. c Table showing PAX3-High and PAX3-Low tumors
from the dataset in (a) and their genetic alterations. Black squares indicate a sample is positive for that alteration. PDGFRA alteration includes
PDGFRA gain, detected either by SNP array or FISH, or mutation (single nucleotide variants, indels, and structural variants), detected by
whole-genome sequencing. d Age at diagnosis of PAX3-Low versus PAX3-High human BSG. e Schematic of the human brain showing the
regional differences in Pax3 expression in glioma.
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http://www.actaneurocomms.org/content/2/1/134pediatric gliomas arising in the cerebral cortex (supra-
tentorial) and the brainstem (infratentorial) (Figure 7e).
Discussion
Brainstem Glioma (BSG) is a distinct disease, biologically
and clinically, from glioma of the cerebral cortex (CG).
While decades of research has provided insight into the
cellular, molecular, and genetic alterations occurring in
CG and guided therapeutic strategies for that disease, the
field of BSG research is still in its infancy. In an effort to
identify unique characteristics of BSG, we compared geneexpression profiles of mouse PDGF-B-induced BSG and
CG, and identified 23 genes that are differentially regulated
between gliomas arising in the two regions. Among those
genes, 8 were associated with the gliomagenesis process in
the brainstem but not in the cerebral cortex—these genes
we identify as “brainstem-specific gliomagenesis genes”. Of
these genes, Pax3, Irx5, and Chl1 were also differentially
regulated between the Olig2-compartments of BSG and
CG suggesting that they represent biological differences
within the tumor cells. As Olig2 characterizes the majority
of human BSG, particularly the oligodendroglial (PDGFRA)
Table 2 Genetic alterations associated with Pax3
expression in human Brainstem Glioma
Genetic alteration Pax3-low Pax3-high P-valueb
ACVR1 mutation 6/11 0/11 *0.01
PDGFRA alterationa 1/11 7/11 *0.02
CDK4/6-CCND1/2/3 amp 1/11 7/11 *0.02
TP53 alteration 4/11 9/11 0.08
PPM1D mutation 3/11 0/11 0.2
Histone H3.3-K27M 6/11 9/11 0.4
Histone H3.1-K27M 2/11 0/11 0.5
aIncludes PDGFRA gain, detected either by SNP array or FISH, or mutation
(single nucleotide variants, indels, and structural variants), detected by
whole-genome sequencing.
bFisher’s Exact Test.
*p-value < 0.05.
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http://www.actaneurocomms.org/content/2/1/134and H3-K27M subgroups [5,8,50,51], as well as marks a
candidate cell-of-origin for BSG [52], the expression profile
of these cells has important implications for at least a sub-
set of the human disease.
Due to the controlled nature of this experiment, the
gene expression signatures identified in this study can
be primarily attributed to regional characteristics of the
brainstem and cerebral cortex. It has not been previ-
ously reported that gliomas induced with the same gen-
etic alterations in different regions of the mouse brain
have distinct gene expression. We have found mouse
BSG to harbor a distinct expression pattern of developmen-
tal homeobox genes and transcription factors, including
Pax3, Irx5, Foxg1, and Lhx2. Overall, these observations are
similar to those made by others in comparing human infra-
tentorial to supratentorial low-grade glioma [20], and BSG
to other pediatric high-grade glioma [5]. The latter study
did not include PAX3 in their list of genes upregulated in
BSG, however, potentially due to the inclusion of thalamic
gliomas in their high-grade glioma group, some of which
could harbor high PAX3 expression.
Herein is the first report of Pax3 expression in BSG. Im-
portantly, we find regional expression of Pax3 in mouse
PDGF-B-driven glioma in the context of Ink4aARF-loss,
p53-loss, and overexpression of H3.3-K27M that is mir-
rored in human glioma. PAX3 mRNA is expressed at
higher levels in BSG compared to CG in two independent
sets of human samples, which include both pre-treatment
biopsies and post-treatment autopsies. The analyses also
revealed that approximately 40% of human BSG harbor
relatively high PAX3 expression and that these tumors as-
sociate with increased PDGFRA signaling and alterations
of cell-cycle regulatory genes, both of which characterize
our PDGF-B-driven BSG mouse model. The majority of
PAX3-High tumors also contain TP53 alterations and the
H3.3-K27M mutation, genetic alterations that also coexist
with Pax3 expression in our mouse model. Collectively,
these data suggest that PAX3-High tumors may be part ofthe oligodendroglial and the H3-K27M subgroups previ-
ously described to harbor PDGFRA alterations [5,10]. In
addition, PPM1D, H3.1-K27M, and ACVR1 mutations
occur only in PAX3-Low tumors. ACVR1 mutations have
also been reported to be mutually exclusive of PDGFRA
alterations [11,13], although as we did not observe a link
between PDGF signaling and PAX3 expression, we believe
the exclusivity between high PAX3 and ACVR1 mutation
to be independent of PDGFRA. Consistent with ACVR1
mutations occurring in younger patients [11], Pax3-High
(and thus ACVR1 wildtype) tumors are associated with
older patients in this study.
The regional expression pattern of Pax3 in glioma corre-
lates with its expression in the developing mouse brain,
pointing to the possibility that the expression level of Pax3
in different regions of the developing brain dictate its ex-
pression level in gliomas arising in those regions. It is
plausible that Pax3 is highly expressed in BSG because the
gliomagenesis process prevents its normal downregulation,
although this has not been directly tested. In support of
this, however, several populations of Pax3-positive pro-
genitor cells exist throughout the P3 mouse brainstem.
A subset of these cells co-express the stem/progenitor
cell marker Nestin, particularly in the dorsal pons and
midbrain, locations in the mouse in which Pax3-High
BSG are localized. As Nestin cells are the targeted cell-
of-origin for the BSG model used here, it is possible that
Nestin+/Pax3+ progenitors give rise to Pax3-High glioma
in this mouse model. Although a Nestin+ cell is a candidate
cell-of-origin for human glioma [53], the cell type(s) and
the location of the cell(s) giving rise to human BSG specific-
ally are still in question. The majority of human BSG are at
diagnosis localized primarily to the ventral pons, suggesting
a potential ventral location for the cell-of-origin [52]. This
would be in contradiction to a dorsal Nestin+/Pax3+ cell-
of-origin as discussed here, and represents a limitation of
this model. However we do not yet know the identity or
location of any Nestin+/Pax3+ progenitors in the develop-
ing human pons, and as there are significant differences
between mouse and human brainstem anatomy, we can-
not be certain that the dorsal Nestin+/Pax3+ progenitors
identified here in the mouse correlate with a dorsal loca-
tion in the human pons. Further investigation into the
expression of Pax3 along with other glioma markers in
the developing mouse and human brainstem will be the
focus of future studies to hopefully clarify this issue.
Investigation into the function of Pax3 in the brainstem
revealed that ectopically expressed Pax3 is not oncogenic
in the absence of any other genetic alterations. While
in vitro, Pax3 overexpression inhibits basal apoptosis, this
effect is insufficient to induce tumor formation in vivo.
When combined with the pro-proliferative effects of in-
creased PDGF signaling, a common event found in PAX3-
High human BSG, ectopic Pax3 enhances gliomagenesis,
Misuraca et al. Acta Neuropathologica Communications 2014, 2:134 Page 14 of 17
http://www.actaneurocomms.org/content/2/1/134increasing tumor frequency and promoting progression to
a high-grade malignancy. Although we are unable to de-
termine the percentage of tumor cells expressing both ec-
topic PDGF-B and Pax3 in this model, the survival
advantage associated with both seen here suggests that the
tumorigenesis process would select for doubly infected
cells.
Pax3-induced inhibition of apoptosis is seemingly
dependent on p53, as deletion of p53 in brainstem pro-
genitors in vitro abolishes the anti-apoptotic effects of
Pax3. This is in accordance with literature describing a
direct interaction between Pax3 and p53 proteins leading
to degradation of p53 [30,54]. Interestingly, in the ab-
sence of p53, Pax3 promotes the proliferation of brain-
stem progenitors, which may explain how deletion of
Pax3 in p53-deficient BSG delays gliomagenesis in vivo.
These pro-survival effects of Pax3 suggest that it can co-
operate with other oncogenic drivers, either through in-
hibition of p53-dependent apoptosis or by promoting
proliferation, functions that it provides to other types of
cancer cells, including glioblastoma cell lines [33,55-57].
It should be noted that the in vitro experiments de-
scribed here were conducted in the presence of serum,
which induces differentiation. As Pax3 function is most
likely dependent upon differentiation status, studying the
effects of Pax3 in the context of stem cell conditions
should be a focus of future research.
Collectively, our functional data suggest that Pax3 is
able to promote the initiation as well as the progression
of brainstem gliomagenesis when combined with other
genetic alterations. As Pax3 has been found expressed in
cerebral cortex glioma [32], infratentorial low-grade gli-
oma [20], as well as high grade BSG as shown here, it ap-
pears that Pax3 is expressed in glioma (albeit at different
levels) regardless of the tumor grade or location, and may
play a functional role in all scenarios dependent on the
context of additional genetic alterations. We find here that
Pax3 increases the frequency of both low- and high-grade
BSG in the context of PDGF signaling, supporting its role
as an oncogene in both low- and high-grade brainstem le-
sions. Although results herein show a lack of Pax3 upreg-
ulation and function in cerebral cortex gliomas of mice,
Chen et al. showed that Pax3 levels correlate with increas-
ing WHO grade of supratentorial gliomas [32] and subse-
quently Xia et al. showed that Pax3 functionally promotes
survival of GBM cell lines and xenografts originally iso-
lated from supratentorial tumors [33]. Based on our direct
comparison between BSG and CG, we would expect the
levels of Pax3 expression in these supratentorial gliomas
to be lower than in BSG. The functional discrepancies
could be explained by varying contexts of genetic alter-
ations, differences between mouse and human tumor biol-
ogy, or an inhibitory effect on Pax3 expression or function
of the cerebral cortex stroma in mice.In summary, the data presented here show that mouse
BSG and a subset of human BSG highly express Pax3, dis-
tinguishing these tumors from gliomas arising in the cere-
bral cortex. This expression pattern of Pax3 is mirrored in
the developing brain, which may account for the gene’s re-
gional specificity in glioma. We have identified a subset of
human BSG with high PAX3 expression that associates
with PDGFRA alterations and amplification of cell-
cycle regulatory genes, and is exclusive of ACVR1 muta-
tions. Functional studies show that in addition to being a
regional marker for BSG, Pax3 also inhibits apoptosis and
promotes proliferation of brainstem progenitor cells, and
contributes to PDGF-B-induced brainstem gliomagenesis
in vivo. Important complements to these studies in the fu-
ture will be to investigate the function of Pax3 in human
BSG cells, both in cell lines and xenografts, as well as in
epigenetically-induced models to study how the presence
of the H3.3-K27M mutation contributes to or alters
Pax3 function. Further investigation into the mecha-
nisms upstream and downstream of Pax3 will increase
our understanding of this subset of BSG and may lead
to the identification of targets or pathways that could
be exploited for therapeutic purposes.Additional files
Additional file 1: Table S1. Differentially expressed genes between
mouse normal cortex (NC) and Cerebral Cortex Glioma (CG), FDR-adjusted
p-value < 0.05, fold-change ≥ 2.
Additional file 2: Table S2. Differentially expressed genes between
mouse normal brainstem (NBS) and Brainstem Glioma (BSG),
FDR-adjusted p-value < 0.05, fold-change ≥ 2.
Additional file 3: Table S3. Differentially expressed genes between
mouse Brainstem Glioma (BSG) and Cerebral Cortex Glioma (CG),
FDR-adjusted p-value < 0.05, fold-change ≥ 2.
Additional file 4: Figure S1. Regional differences in Olig2-Glioma cell
compartments. a Kaplan-Meier survival curve of Ntv-a;Ink4a-ARF−/−;Olig2-
eGFP-L10a mice injected with RCAS-PDGF-B into the brainstem or
cerebral cortex at P2-4 to generate Brainstem Glioma (BSG) and Cerebral
Cortex Glioma (CG), respectively. b Gliomas from (a) were harvested,
dissociated, and sorted into GFP + and GFP- compartments by FACS and
the GFP + BSG and CG samples (n = 3 for each) were compared using
expression profiling. Shown is hierarchical clustering of 118 genes
differentially regulated between BSG and CG Olig2-cells. p <0.01 and
fold change ≥2.0.
Additional file 5: Table S4. Differentially expressed genes between
Olig2-eGFP-L10a gliomas initiated in the brainstem (BS) and the cerebral
cortex (CX), p-value < 0.01 and fold change ≥2.0.
Additional file 6: Figure S2. Regional expression of Pax3 in the
neonatal mouse brain. a Immunofluorescence for PAX3 (red) in P3 Ntv-a
pons. Nuclei are stained with DAPI (blue). 10x magnification, scale bar is
100 μM. White boxes indicate dorsal, mid, and ventral pons populations
of PAX3-expressing cells. 4th ventricle and Cerebellum (Cb) are
indicated for reference. b-c Immunofluorescence for PAX3 (red) and
DAPI (blue), upper panels; PAX3 (red) and Nestin-CFP (green), lower
panels. 20x magnification, scale bar is 50 μM. b mid pons, c 4th ventricle
floor: left panels are representative of the majority of sections analyzed
in which the Nestin-progenitors lining the ventricle are negative for
PAX3. Right panels are representative of rare sections in which a subset
of the Nestin-progenitors lining the ventricle expresses PAX3.
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http://www.actaneurocomms.org/content/2/1/134Additional file 7: Figure S3. Normal brainstem progenitors isolated
from P3 Ntv-a mice were infected with RCAS-Y, RCAS-Pax3, RCAS-PDGF-B,
or RCAS-Pax3 + RCAS-PDGF-B. a mRNA from infected cells was isolated
and analyzed for PDGF-B expression by RT-PCR. PCR primers for PDGF-B
amplify endogenous mouse PDGF-B as well as the human RCAS-PDGF-
B. b BrdU incorporation of normal brainstem progenitors from Ntv-a P3
mice infected with the RCAS viruses as indicated below the graph
(RCAS-Y vector was used to control for the total amount of virus).
Data is represented as fold-change over RCAS-Y.
Additional file 8: Figure S4. Ntv-a mice were injected into the cerebral
cortex with DF1 cells expressing RCAS-Pax3, RCAS-PDGF-B, or RCAS-
PDGF-B + RCAS-Pax3 on P2-4, and monitored for signs and symptoms of
brain tumors. a Kaplain-Meier survival curve; p = 0.5, PDGF-B vs. PDGF-B +
Pax3. b Mice from the experiment in (a) were sacrificed at the onset of
tumor symptoms, or at 12 weeks in the absence of symptoms, and the
brains of all mice were analyzed for the presence of glioma using
hematoxylin and eosin (H&E) staining, and their tumors graded as described
in Materials and Methods. Shown is the percentage of mice in each group
with no tumor, grade II, III, and IV glioma.
Additional file 9: Figure S5. Deletion of Pax3 in p53-deficient Brainstem
Glioma. Ntv-a;p53fl/fl mice (Control) and Ntv-a;p53fl/fl;Pax3fl/fl mice (Pax3-KO)
were injected with RCAS-PDGF-B + RCAS-Cre into the brainstem at
P2-4. Representative Control and Pax3-KO tumors were analyzed for
recombination of the Pax3-floxed allele by PCR of gDNA (a) and for
PAX3 protein expression by Western blot (b).
Additional file 10: Table S5. Differentially expressed genes between
human Brainstem Glioma (Brainstem) and Cerebral Cortex Glioma
(Cortical) from post-treatment autopsy samples, FDR-adjusted
p-value < 0.05.
Additional file 11: Table S6. Differentially expressed genes between
human Brainstem Glioma (Brainstem) and Cerebral Cortex Glioma
(Cortical) from pre-treatment biopsy samples, FDR-adjusted
p-value < 0.05.
Additional file 12: Table S7. Differentially expressed genes between
PAX3-High and PAX3-Low Brainstem Glioma post-treatment autopsy
samples, FDR-adjusted p-value < 0.05.
Additional file 13: Table S8. Differentially expressed genes between
PAX3-High and PAX3-Low Brainstem Glioma pre-treatment biopsy
samples, FDR-adjusted p-value < 0.05.
Additional file 14: Table S9. Genetic alterations associated with Pax3
expression in human Brainstem Glioma samples.
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